KINIKSA PHARMACEUTICALS INTE (KNSA) Stock News

USA - NASDAQ:KNSA - GB00BRXB0C07 - Common Stock

39.045 USD

+0.19 (+0.48%)

Last: 10/16/2025, 2:49:04 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KNSA Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Chartmill

News Image

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen

17 days ago - By: Benzinga

What Analysts Are Saying About Kiniksa Pharmaceuticals Stock

a month ago - By: Zacks Investment Research - Mentions: ZTS CRMD PHAR

Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain

a month ago - By: Zacks Investment Research - Mentions: RARE CRMD PHAR

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

a month ago - By: Zacks Investment Research - Mentions: CRMD IMVT PHAR

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

a month ago - By: Zacks Investment Research - Mentions: BMY CYTK CRMD

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

a month ago - By: Zacks Investment Research - Mentions: CRMD EDIT PHAR

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

a month ago - By: Zacks Investment Research

Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why

a month ago - By: Zacks Investment Research - Mentions: POST TME

Court Ruling & Tariff Uncertainty: Time to Bet on POST, TME & KNSA?

2 months ago - By: Zacks Investment Research - Mentions: ALNY CRMD

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

2 months ago - By: Zacks Investment Research - Mentions: CRMD OTLK PHAR

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

2 months ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

2 months ago - By: Zacks Investment Research - Mentions: INO CRMD PGEN

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

2 months ago - By: Zacks Investment Research - Mentions: CPRX CRMD PHAR

Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

2 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Kiniksa Pharmaceuticals International, plc (KNSA) Could Rally 26.69%: Here's is How to Trade

2 months ago - By: Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why

2 months ago - By: Zacks Investment Research - Mentions: TPC ESEA MOD LIF

Zacks.com featured highlights include Modine Manufacturing, Tutor Perini, Kiniksa Pharmaceuticals International and Euroseas

2 months ago - By: Zacks Investment Research - Mentions: GSK TBPH CRMD

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

2 months ago - By: Zacks Investment Research - Mentions: TPC ESEA MOD LIF

5 Stocks With Recent Price Strength Amid Trade & Rate Cut Uncertainties

2 months ago - By: Zacks Investment Research

Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know

2 months ago - By: Investor's Business Daily - Mentions: GILD AUPH INCY

Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?

3 months ago - By: Zacks Investment Research

Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge

3 months ago - By: Zacks Investment Research

Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?

3 months ago - By: Zacks Investment Research

Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going

3 months ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

3 months ago - By: Benzinga

Earnings Preview: Kiniksa Pharmaceuticals

3 months ago - By: Kiniksa Pharmaceuticals International, Plc

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

4 months ago - By: The Motley Fool

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

4 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

5 months ago - By: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences